Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 39.00 | |
10 mg | In stock | $ 59.00 | |
25 mg | In stock | $ 122.00 | |
50 mg | In stock | $ 189.00 | |
100 mg | In stock | $ 288.00 | |
200 mg | In stock | $ 428.00 | |
500 mg | In stock | $ 686.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 43.00 |
Description | Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis. |
In vitro | Pivanex has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Pivanex (200 μM) causes enhancement in the G2-M phase, moderate enhancement in the S phase, and a slight reduction in G0-G1 of the cell cycle. Pivanex (100-500 μM) shows significant anti-proliferation activity in K562 cells. Pivanex (100-500 μM) also increases apoptosis and caspase activity in K562 cells [1][2]. |
In vivo | Pivanex treatment also marked delays in the end stage of disease as defined by the onset of body mass loss. Pivanex (200 mg/kg, b.i.d, daily) obviously improves the survival of SMN7 SMA mice [3]. |
Synonyms | Pivalyloxymethyl butyrate, AN-9 |
Molecular Weight | 202.25 |
Formula | C10H18O4 |
CAS No. | 122110-53-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (494.44 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pivanex 122110-53-6 Angiogenesis Apoptosis Chromatin/Epigenetic Cytoskeletal Signaling DNA Damage/DNA Repair Tyrosine Kinase/Adaptors HDAC Bcr-Abl Chronic leukemia muscular Acute ALL atrophy Inhibitor lung Pivalyloxymethyl butyrate Histone deacetylases NSCLC myelogenous lymphoblastic AN9 cancer CML AN 9 spinal K562 inhibit AN-9 Pivalyloxymethyl Butyrate inhibitor